Comparing C R Bard (BCR) & Intersect ENT (XENT)

C R Bard (NYSE: BCR) and Intersect ENT (NASDAQ:XENT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares C R Bard and Intersect ENT’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
C R Bard 9.51% 19.39% 6.91%
Intersect ENT -19.81% -15.96% -14.16%

Analyst Recommendations

This is a summary of current ratings and recommmendations for C R Bard and Intersect ENT, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C R Bard 0 7 0 0 2.00
Intersect ENT 0 2 8 0 2.80

C R Bard presently has a consensus target price of $310.60, suggesting a potential downside of 6.23%. Intersect ENT has a consensus target price of $33.43, suggesting a potential downside of 9.41%. Given C R Bard’s higher probable upside, equities analysts plainly believe C R Bard is more favorable than Intersect ENT.

Insider and Institutional Ownership

79.1% of C R Bard shares are owned by institutional investors. Comparatively, 85.5% of Intersect ENT shares are owned by institutional investors. 0.8% of C R Bard shares are owned by company insiders. Comparatively, 13.7% of Intersect ENT shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

C R Bard has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Valuation & Earnings

This table compares C R Bard and Intersect ENT’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
C R Bard $3.71 billion 6.50 $531.40 million $7.59 43.64
Intersect ENT $78.71 million 13.81 -$25.22 million ($0.62) -59.52

C R Bard has higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than C R Bard, indicating that it is currently the more affordable of the two stocks.

Dividends

C R Bard pays an annual dividend of $0.78 per share and has a dividend yield of 0.2%. Intersect ENT does not pay a dividend. C R Bard pays out 10.3% of its earnings in the form of a dividend. C R Bard has raised its dividend for 46 consecutive years.

Summary

C R Bard beats Intersect ENT on 10 of the 17 factors compared between the two stocks.

C R Bard Company Profile

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Intersect ENT Company Profile

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply